AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2026
Jan 8, 2026
33483_dirs_2026-01-08_42af5bb3-cc87-4e0b-b5cf-be9d2828a8ed.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2026-01-06
Reporting Person: Brunn Carsten (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-06 | Common Stock | S | 23766 | $6.8197 | Disposed | 323530 | Direct |
Footnotes
F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
More from Cartesian Therapeutics, Inc.
Capital/Financing Update
2026
May 26
Share Issue/Capital Change
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Earnings Release
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Board/Management Information
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Investor Presentation
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8